PTAB proceedings catching on with pharma industry
Patent Trial and Appeal Board proceedings are increasingly popular among pharma firms, in particular among generics eager to find a new way to invalidate big pharma’s patents. Marion Webb reports
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: